|
FY 2016
|
|
Q4 2016
|
||||
|
$m
|
% change
|
$m
|
% change
|
|||
|
CER1
|
Actual
|
CER
|
Actual
|
|||
Total Revenue
|
23,002
|
(5)
|
(7)
|
5,585
|
(12)
|
(13)
|
|
Product Sales
|
21,319
|
(8)
|
(10)
|
5,260
|
(15)
|
(15)
|
|
Externalisation Revenue
|
1,683
|
59
|
58
|
325
|
77
|
69
|
|
|
|
|
|
|
|
|
|
Reported Operating Profit
|
4,902
|
9
|
19
|
2,533
|
n/m
|
n/m
|
|
Core Operating Profit2
|
6,721
|
(7)
|
(3)
|
2,026
|
15
|
30
|
|
|
|
|
|
|
|
|
|
Reported Earnings Per Share (EPS)
|
$2.77
|
9
|
24
|
$1.46
|
93
|
n/m
|
|
Core EPS
|
$4.31
|
(5)
|
1
|
|
$1.21
|
9
|
29
|
Regulatory
Submission Acceptances
|
- durvalumab - bladder cancer (US)
- Tagrisso - lung cancer (AURA3 trial) (US,
EU)
- Faslodex - breast cancer (1st line) (US,
EU)
- roxadustat - anaemia (CN) (rolling
submission)
- benralizumab - severe, uncontrolled asthma (US,
EU)
|
Other
Key Developments
|
- Priority Review Designation: durvalumab
(US)
- Priority Review Designation: Tagrisso (US)
|
Total Revenue
|
A low
to mid single-digit percentage decline
|
Core EPS
|
A low
to mid teens percentage decline*
|
H1
2017
|
Faslodex - breast cancer (1st line): Regulatory decision
(JP)
Lynparza - ovarian cancer (2nd line): Regulatory
submission
Lynparza - breast cancer: Data readout
Tagrisso - lung cancer (AURA3): Regulatory decision
(US)
durvalumab
- bladder cancer: Regulatory decision (US)
durva
+/- treme - lung cancer (ARCTIC): Data readout
acalabrutinib - blood cancer: Data readout, regulatory submission
(US) (Phase II)#
Bydureon - autoinjector:
Regulatory submission (US)
saxagliptin/dapagliflozin -
type-2 diabetes: Regulatory decision (US)
ZS-9 (sodium zirconium cyclosilicate) - hyperkalaemia: Regulatory decision (US,
EU)
Bevespi - COPD: Regulatory submission (EU)
benralizumab - severe, uncontrolled asthma: Regulatory submission
(JP)
|
Mid-2017
|
durva
+/- treme - lung cancer (MYSTIC): Data readout
|
H2
2017
|
Faslodex - breast cancer (1st line): Regulatory decision
(US, EU)
Lynparza - breast cancer: Regulatory submission
Lynparza - ovarian cancer (1st
line): Data readout
Tagrisso - lung cancer:
Regulatory decision (CN)Tagrisso - lung cancer (AURA3): Regulatory decision
(EU)
Tagrisso - lung cancer (1st
line): Data readout
durvalumab
- lung cancer (PACIFIC): Data readout, regulatory submission
(US)
durva +/- treme - lung cancer (MYSTIC): Regulatory
submission
durva +/- treme - lung cancer (ARCTIC): Regulatory
submission
durva +/- treme - head & neck cancer (KESTREL): Data readout
moxetumomab - leukaemia: Data readout
benralizumab - severe, uncontrolled asthma: Regulatory decision
(US)
tralokinumab - severe, uncontrolled asthma: Data
readout
|
2018
|
Lynparza - ovarian cancer (1st line): Regulatory
submission
Tagrisso - lung cancer (1st line): Regulatory
submission
durva +
treme - lung cancer (NEPTUNE): Data readout
durva +/- treme - head & neck cancer (KESTREL): Regulatory
submission
durva
+/- treme - head & neck cancer (EAGLE): Data readout,
regulatory submission
durva
+/- treme - bladder cancer (DANUBE): Data readout, regulatory
submission
moxetumomab
- leukaemia: Regulatory submission
selumetinib
- thyroid cancer: Data readout, regulatory submission
Brilinta - type-2 diabetes / coronary artery disease: Data
readout, regulatory submission
Bydureon - cardiovascular (CV) outcomes trial: Data readout, regulatory
submission
roxadustat
- anaemia: Data readout
(AstraZeneca-sponsored trials), regulatory
submission
Duaklir - COPD: Regulatory submission (US)
benralizumab
- severe, uncontrolled asthma: Regulatory decision
(EU)
tralokinumab
- severe, uncontrolled asthma: Regulatory submission
PT010 -
COPD: Data readout, regulatory submission
anifrolumab
- lupus: Data
readout
|
Media
Enquiries
|
|||
Esra
Erkal-Paler
|
UK/Global
|
+44 203
749 5638
|
|
Neil
Burrows
|
UK/Global
|
+44 203
749 5637
|
|
Vanessa
Rhodes
|
UK/Global
|
+44 203
749 5736
|
|
Karen
Birmingham
|
UK/Global
|
+44 203
749 5634
|
|
Rob
Skelding
|
UK/Global
|
+44 203
749 5821
|
|
Jacob
Lund
|
Sweden
|
+46
8 553 260 20
|
|
Michele
Meixell
|
US
|
+1 302
885 2677
|
|
Investor
Relations
|
|||
Thomas
Kudsk Larsen
|
|
+44 203
749 5712
|
|
Craig
Marks
|
Finance,
Fixed Income, M&A
|
+44
7881 615 764
|
|
Henry
Wheeler
|
Oncology
|
+44 203
749 5797
|
|
Mitchell
Chan
|
Oncology
|
+1 240
477 3771
|
|
Lindsey
Trickett
|
Cardiovascular
& Metabolic Diseases
|
+1 240
543 7970
|
|
Nick
Stone
|
Respiratory
|
+44 203
749 5716
|
|
Christer
Gruvris
|
Autoimmunity,
Neuroscience & Infection
|
+44 203
749 5711
|
|
US toll
free
|
|
+1 866
381 7277
|
|
|
FY 2016
|
Q4 2016
|
||
$m
|
% CER change
|
$m
|
% CER change
|
|
Product
Sales
|
21,319
|
(8)
|
5,260
|
(15)
|
Externalisation
Revenue
|
1,683
|
59
|
325
|
77
|
Total Revenue
|
23,002
|
(5)
|
5,585
|
(12)
|
Growth Platform
|
FY 2016
|
Q4 2016
|
||
Product Sales ($m)
|
% CER change
|
Product Sales ($m)
|
% CER change
|
|
Emerging
Markets
|
5,794
|
6
|
1,486
|
7
|
Respiratory
|
4,753
|
(3)
|
1,210
|
(5)
|
Diabetes
|
2,427
|
11
|
598
|
3
|
Japan
|
2,184
|
(3)
|
591
|
(5)
|
Brilinta
|
839
|
39
|
236
|
37
|
New
Oncology1
|
664
|
n/m
|
216
|
n/m
|
Total2
|
14,491
|
5
|
3,728
|
3
|
|
FY 2016
|
Q4 2016
|
||||||
|
$m
|
% of Total
|
% change
|
$m
|
% of Total
|
% change
|
||
|
CER
|
Actual
|
CER
|
Actual
|
||||
Royalties2
|
119
|
7
|
69
|
58
|
45
|
14
|
222
|
230
|
Milestones
|
237
|
14
|
35
|
33
|
10
|
3
|
(87)
|
(87)
|
Sub-total Sustainable and Ongoing Externalisation
Revenue
|
356
|
21
|
45
|
40
|
55
|
17
|
(37)
|
(40)
|
Upfront Receipts
|
1,327
|
79
|
63
|
63
|
270
|
83
|
172
|
171
|
Total Externalisation Revenue
|
1,683
|
100
|
59
|
58
|
325
|
100
|
77
|
69
|
Medicine
|
Partner
|
Region
|
$m
|
Anaesthetics
|
Aspen -
initial revenue
|
Global
(excl. US)
|
520
|
Plendil
|
China
Medical System Holdings Ltd -commercialisation rights - initial
revenue
|
China
|
298
|
Toprol-XL
|
Aralez
Pharmaceuticals Trading DAC (Aralez) - initial revenue
|
US
|
175
|
Tralokinumab - atopic dermatitis
|
LEO
Pharma A/S (LEO Pharma) - initial revenue
|
Global
|
115
|
AZD3293
|
Eli
Lilly and Company (Lilly) - milestone revenue
|
Global
|
100
|
Nexium OTC
20mg
|
Pfizer
Inc. (Pfizer) - milestone revenue
|
Global
|
93
|
Moventig
|
ProStrakan
Group plc - commercialisation rights - initial and milestone
revenue
|
EU
|
78
|
Others
|
|
|
304
|
Total
|
|
|
1,683
|
Announcement Date
|
Medicine
|
Partner
|
Region
|
Externalisation Revenue
|
4 October
2016
|
Toprol-XL
|
Aralez
|
US
|
●
Initial $175m milestone
●
Up to $48m milestone and sales-related
revenue
●
Mid-teen percentage royalties on
sales
|
1 July
2016
|
Tralokinumab - atopic dermatitis
|
LEO
Pharma
|
Global
|
●
Initial $115m milestone
●
Up to $1bn in commercially-related
milestones
●
Up to mid-teen tiered percentage royalties on
sales
|
9 June
2016
|
Anaesthetics
|
Aspen
|
Global
(excl. US)
|
●
Initial $520m milestone
●
Up to $250m in sales-related
revenue
●
Double-digit percentage trademark royalties on
sales
|
1 September
2015
|
Brodalumab - psoriasis
|
Valeant
Pharmaceuticals International, Inc. (Valeant)
|
Global,
later
amended
to US
|
●
Initial $100m milestone
●
Pre-launch milestone up to $170m
●
Sales-related royalties up to
$175m
|
19 March
2015
|
Movantik
|
Daiichi
Sankyo
|
US
|
●
Initial $200m milestone
●
Up to $625m in Product Sales-related
revenue
|
|
FY 2016
|
Q4 2016
|
|||||
|
$m
|
% of Total
|
% change
|
$m
|
% change
|
||
|
CER
|
Actual
|
CER
|
Actual
|
|||
Oncology
|
|
|
|
|
|
|
|
Iressa
|
513
|
2
|
(5)
|
(6)
|
118
|
(11)
|
(9)
|
Tagrisso
|
423
|
2
|
n/m
|
n/m
|
147
|
n/m
|
n/m
|
Lynparza
|
218
|
1
|
n/m
|
n/m
|
62
|
72
|
72
|
Legacy:
|
|
|
|
|
|
|
|
Faslodex
|
830
|
4
|
19
|
18
|
222
|
19
|
20
|
Zoladex
|
816
|
4
|
-
|
-
|
235
|
13
|
19
|
Casodex
|
247
|
1
|
(9)
|
(7)
|
60
|
(8)
|
(5)
|
Arimidex
|
232
|
1
|
(6)
|
(7)
|
57
|
(7)
|
(5)
|
Others
|
104
|
-
|
(26)
|
(21)
|
29
|
-
|
12
|
Total Oncology
|
3,383
|
16
|
20
|
20
|
930
|
26
|
30
|
Cardiovascular & Metabolic Diseases
|
|
|
|
|
|
|
|
Brilinta
|
839
|
4
|
39
|
36
|
236
|
37
|
36
|
Farxiga
|
835
|
4
|
72
|
70
|
239
|
57
|
57
|
Onglyza
|
720
|
3
|
(6)
|
(8)
|
149
|
(21)
|
(22)
|
Bydureon
|
578
|
3
|
-
|
-
|
142
|
(8)
|
(8)
|
Byetta
|
254
|
1
|
(19)
|
(20)
|
55
|
(22)
|
(24)
|
|
|
|
|
|
|
|
|
Legacy:
|
|
|
|
|
|
|
|
Crestor
|
3,401
|
16
|
(32)
|
(32)
|
631
|
(53)
|
(52)
|
Seloken/Toprol-XL
|
737
|
3
|
9
|
4
|
178
|
14
|
11
|
Atacand
|
315
|
1
|
(8)
|
(13)
|
81
|
(5)
|
(6)
|
Others
|
437
|
2
|
(26)
|
(28)
|
100
|
(31)
|
(32)
|
Total Cardiovascular & Metabolic Diseases
|
8,116
|
38
|
(13)
|
(14)
|
1,811
|
(26)
|
(26)
|
Respiratory
|
|
|
|
|
|
|
|
Symbicort
|
2,989
|
14
|
(10)
|
(12)
|
740
|
(13)
|
(14)
|
Pulmicort
|
1,061
|
5
|
8
|
5
|
288
|
8
|
5
|
Tudorza/Eklira
|
170
|
1
|
(9)
|
(11)
|
36
|
(23)
|
(23)
|
Daliresp/Daxas
|
154
|
1
|
48
|
48
|
41
|
28
|
28
|
Duaklir
|
63
|
-
|
n/m
|
n/m
|
19
|
58
|
58
|
Others
|
316
|
1
|
27
|
22
|
86
|
37
|
32
|
Total Respiratory
|
4,753
|
22
|
(3)
|
(5)
|
1,210
|
(5)
|
(6)
|
Other
|
|
|
|
|
|
|
|
Nexium
|
2,032
|
10
|
(18)
|
(19)
|
491
|
(15)
|
(13)
|
Seroquel XR
|
735
|
3
|
(27)
|
(28)
|
118
|
(51)
|
(51)
|
Synagis
|
677
|
3
|
2
|
2
|
302
|
10
|
10
|
Losec/Prilosec
|
276
|
1
|
(17)
|
(19)
|
59
|
(23)
|
(23)
|
FluMist/Fluenz
|
104
|
-
|
(59)
|
(64)
|
67
|
(60)
|
(65)
|
Movantik/Moventig
|
91
|
-
|
n/m
|
n/m
|
26
|
73
|
73
|
Others
|
1,152
|
5
|
(20)
|
(23)
|
246
|
(34)
|
(35)
|
Total Other
|
5,067
|
24
|
(19)
|
(20)
|
1,309
|
(25)
|
(25)
|
Total Product Sales
|
21,319
|
100
|
(8)
|
(10)
|
5,260
|
(15)
|
(15)
|
|
FY 2016
|
Q4 2016
|
|
||||||
|
$m
|
% of Total
|
% change
|
$m
|
% change
|
|
|||
|
CER
|
Actual
|
CER
|
Actual
|
|
||||
US
|
7,365
|
35
|
(22)
|
(22)
|
1,618
|
(37)
|
(37)
|
|
|
Europe
|
5,064
|
24
|
(3)
|
(5)
|
1,332
|
(3)
|
(6)
|
|
|
Established
ROW1
|
3,096
|
15
|
(4)
|
2
|
824
|
(6)
|
5
|
|
|
|
Japan
|
2,184
|
10
|
(3)
|
8
|
591
|
(5)
|
9
|
|
|
Canada
|
497
|
2
|
(2)
|
(7)
|
126
|
(5)
|
(6)
|
|
|
Other Established ROW
|
415
|
2
|
(10)
|
(12)
|
107
|
(10)
|
(4)
|
|
Emerging
Markets2
|
5,794
|
27
|
6
|
-
|
1,486
|
7
|
4
|
|
|
|
China
|
2,636
|
12
|
10
|
4
|
609
|
8
|
2
|
|
|
Ex. China
|
3,158
|
15
|
3
|
(4)
|
877
|
6
|
5
|
|
Total
|
21,319
|
100
|
(8)
|
(10)
|
5,260
|
(15)
|
(15)
|
|
Medicine
|
Region
|
Externalisation / Disposal Completion Date
|
FY 2015Impacted RegionProduct Sales ($m)
|
Bydureon
& Byetta
|
China
|
11 October 2016
|
15
|
Anaesthetics
|
Global
(excl. US)
|
1 September 2016
|
594
|
Plendil
|
China
|
29 February 2016
|
189
|
Moventig
|
Europe
|
1 March 2016
|
1
|
Toprol-XL
|
US
|
31 October 2016
|
89
|
Imdur
|
Global
(excl. US)
|
3 May 2016
|
55
|
Total
|
|
|
943
|
Year
|
Reported
|
% change
|
|
Core
|
% change
|
||||
FY2016
|
FY2015
|
CER
|
Actual
|
|
FY 2016
|
FY
2015
|
CER
|
Actual
|
|
Product
Sales
|
21,319
|
23,641
|
(8)
|
(10)
|
|
21,319
|
23,641
|
(8)
|
(10)
|
Externalisation
Revenue
|
1,683
|
1,067
|
59
|
58
|
|
1,683
|
1,067
|
59
|
58
|
Total
Revenue
|
23,002
|
24,708
|
(5)
|
(7)
|
|
23,002
|
24,708
|
(5)
|
(7)
|
Cost of
Sales
|
(4,126)
|
(4,646)
|
(7)
|
(11)
|
|
(3,872)
|
(4,119)
|
(2)
|
(6)
|
|
|
|
|
|
|
|
|
|
|
Gross
Profit
|
18,876
|
20,062
|
(5)
|
(6)
|
|
19,130
|
20,589
|
(6)
|
(7)
|
Gross Margin1
|
80.8%
|
80.3%
|
-0.1
|
+0.5
|
|
82.0%
|
82.6%
|
-1.1
|
-0.6
|
|
|
|
|
|
|
|
|
|
|
Distribution
Expense
|
(326)
|
(339)
|
1
|
(4)
|
|
(326)
|
(339)
|
1
|
(4)
|
% Total Revenue
|
1.4%
|
1.4%
|
-
|
-
|
|
1.4%
|
1.4%
|
-
|
-
|
R&D
Expense
|
(5,890)
|
(5,997)
|
2
|
(2)
|
|
(5,631)
|
(5,603)
|
5
|
-
|
% Total Revenue
|
25.6%
|
24.3%
|
-2
|
-1
|
|
24.5%
|
22.7%
|
-2
|
-2
|
SG&A
Expense
|
(9,413)
|
(11,112)
|
(12)
|
(15)
|
|
(8,169)
|
(9,265)
|
(9)
|
(12)
|
% Total Revenue
|
40.9%
|
45.0%
|
+3
|
+4
|
|
35.5%
|
37.5%
|
+1
|
+2
|
Other
Operating Income
|
1,655
|
1,500
|
12
|
10
|
|
1,717
|
1,520
|
14
|
13
|
% Total Revenue
|
7.2%
|
6.1%
|
+1
|
+1
|
|
7.5%
|
6.2%
|
+1
|
+1
|
Operating
Profit
|
4,902
|
4,114
|
9
|
19
|
|
6,721
|
6,902
|
(7)
|
(3)
|
% Total Revenue
|
21.3%
|
16.7%
|
+3
|
+5
|
|
29.2%
|
27.9%
|
-
|
+1
|
Net
Finance Expense
|
(1,317)
|
(1,029)
|
37
|
28
|
|
(661)
|
(505)
|
46
|
31
|
Joint
Ventures
|
(33)
|
(16)
|
|
|
|
(33)
|
(16)
|
|
|
Profit
Before Tax
|
3,552
|
3,069
|
-
|
16
|
|
6,027
|
6,381
|
(11)
|
(6)
|
Taxation
|
(146)
|
(243)
|
|
|
|
(658)
|
(990)
|
|
|
Tax
Rate %
|
4%
|
8%
|
|
|
|
11%
|
16%
|
|
|
Profit
After Tax
|
3,406
|
2,826
|
6
|
21
|
|
5,369
|
5,391
|
(6)
|
-
|
Non-controlling
Interests
|
93
|
(1)
|
|
|
|
86
|
(1)
|
|
|
Net
Profit
|
3,499
|
2,825
|
9
|
24
|
|
5,455
|
5,390
|
(5)
|
1
|
Weighted Average
Shares
|
1,265
|
1,264
|
|
|
|
1,265
|
1,264
|
|
|
Earnings
Per Share ($)
|
2.77
|
2.23
|
9
|
24
|
|
4.31
|
4.26
|
(5)
|
1
|
Quarter
|
Reported
|
% change
|
|
Core
|
% change
|
||||
Q4 2016
|
Q42015
|
CER
|
Actual
|
|
Q42016
|
Q4 2015
|
CER
|
Actual
|
|
Product
Sales
|
5,260
|
6,207
|
(15)
|
(15)
|
|
5,260
|
6,207
|
(15)
|
(15)
|
Externalisation
Revenue
|
325
|
192
|
77
|
69
|
|
325
|
192
|
77
|
69
|
Total
Revenue
|
5,585
|
6,399
|
(12)
|
(13)
|
|
5,585
|
6,399
|
(12)
|
(13)
|
Cost of
Sales
|
(1,160)
|
(1,269)
|
(2)
|
(9)
|
|
(1,087)
|
(1,209)
|
(4)
|
(10)
|
Gross
Profit
|
4,425
|
5,130
|
(15)
|
(14)
|
|
4,498
|
5,190
|
(14)
|
(13)
|
Gross Margin1
|
77.9%
|
79.6%
|
-3.1
|
-1.7
|
|
79.3%
|
80.5%
|
-2.6
|
-1.2
|
Distribution
Expense
|
(83)
|
(99)
|
(11)
|
(16)
|
|
(83)
|
(99)
|
(11)
|
(16)
|
% Total Revenue
|
1.5%
|
1.5%
|
-
|
-
|
|
1.5%
|
1.5%
|
-
|
-
|
R&D
Expense
|
(1,543)
|
(1,746)
|
(5)
|
(12)
|
|
(1,481)
|
(1,567)
|
2
|
(5)
|
% Total Revenue
|
27.6%
|
27.3%
|
-2
|
-
|
|
26.5%
|
24.5%
|
-4
|
-2
|
SG&A
Expense
|
(1,386)
|
(2,668)
|
(44)
|
(48)
|
|
(2,050)
|
(2,461)
|
(14)
|
(17)
|
% Total Revenue
|
24.8%
|
41.7%
|
+15
|
+17
|
|
36.7%
|
38.5%
|
+1
|
+2
|
Other
Operating Income
|
1,120
|
471
|
n/m
|
n/m
|
|
1,142
|
493
|
n/m
|
n/m
|
% Total Revenue
|
20.1%
|
7.4%
|
+13
|
+13
|
|
20.4%
|
7.7%
|
+13
|
+13
|
Operating
Profit
|
2,533
|
1,088
|
n/m
|
n/m
|
|
2,026
|
1,556
|
15
|
30
|
% Total Revenue
|
45.4%
|
17.0%
|
+23
|
+28
|
|
36.3%
|
24.3%
|
+8
|
+12
|
Net
Finance Expense
|
(339)
|
(279)
|
36
|
22
|
|
(172)
|
(150)
|
36
|
15
|
Joint
Ventures
|
(11)
|
(7)
|
|
|
|
(11)
|
(7)
|
|
|
Profit
Before Tax
|
2,183
|
802
|
n/m
|
n/m
|
|
1,843
|
1,399
|
13
|
32
|
Taxation
|
(366)
|
6
|
|
|
|
(333)
|
(200)
|
|
|
Tax
Rate %
|
17%
|
(1)%
|
|
|
|
18%
|
14%
|
|
|
Profit
After Tax
|
1,817
|
808
|
91
|
n/m
|
|
1,510
|
1,199
|
7
|
26
|
Net
Profit
|
1,842
|
808
|
94
|
n/m
|
|
1,533
|
1,199
|
9
|
28
|
|
|
|
|
|
|
|
|
|
|
Weighted Average
Shares
|
1,265
|
1,264
|
|
|
|
1,265
|
1,264
|
|
|
Earnings
Per Share ($)
|
1.46
|
0.63
|
93
|
n/m
|
|
1.21
|
0.94
|
9
|
29
|
FY 2016
|
Reported
|
Restructuring
|
Intangible Asset
Amortisation & Impairments
|
Diabetes Alliance
|
Other1
|
Core
|
$m
|
$m
|
$m
|
$m
|
$m
|
$m
|
|
Cost of
Sales
|
(4,126)
|
130
|
124
|
-
|
-
|
(3,872)
|
R&D
Expense
|
(5,890)
|
178
|
81
|
-
|
-
|
(5,631)
|
SG&A
Expense
|
(9,413)
|
823
|
1,000
|
(627)
|
48
|
(8,169)
|
Other
Operating Income
|
1,655
|
(24)
|
86
|
-
|
-
|
1,717
|
Net
Finance Expense
|
(1,317)
|
-
|
-
|
389
|
267
|
(661)
|
Taxation
|
(146)
|
(232)
|
(307)
|
23
|
4
|
(658)
|
Non-controlling
Interests
|
93
|
(7)
|
-
|
-
|
-
|
86
|
Total
|
|
868
|
984
|
(215)
|
319
|
|
Q4 2016
|
Reported
|
Restructuring
|
Intangible Asset
Amortisation & Impairments
|
Diabetes Alliance
|
Other1
|
Core
|
$m
|
$m
|
$m
|
$m
|
$m
|
$m
|
|
Cost of
Sales
|
(1,160)
|
43
|
30
|
-
|
-
|
(1,087)
|
R&D
Expense
|
(1,543)
|
32
|
30
|
-
|
-
|
(1,481)
|
SG&A
Expense
|
(1,386)
|
319
|
246
|
(938)
|
(291)
|
(2,050)
|
Other
Operating Income
|
1,120
|
-
|
22
|
-
|
-
|
1,142
|
Net
Finance Expense
|
(339)
|
-
|
-
|
97
|
70
|
(172)
|
Taxation
|
(366)
|
(82)
|
(86)
|
162
|
39
|
(333)
|
Non-controlling
Interests
|
25
|
(2)
|
-
|
-
|
-
|
23
|
Total
|
|
310
|
242
|
(679)
|
(182)
|
|
|
$m
|
Sale of
the small-molecule antibiotics business to Pfizer
|
368
net of
carrying values disposed and other costs to sell
|
Sale of
the ex-US rights to Rhinocort
Aqua to Cilag GmbH International (Cilag)
|
321
|
Sale of
ex-US rights of Imdur
|
183
|
Crestor royalties
|
165
|
Out-licensing
of a potential medicine (MEDI2070) for inflammatory diseases to
Allergan plc (Allergan)
|
148
net,
reflecting an agreement with Amgen Inc. (Amgen)
|
HPV
royalties
|
134
|
Other
|
336
|
Total
|
1,655
|
|
|
|
|
Average Exchange Rates Versus USD
|
|
|
|
Impact Of 5% Strengthening In Exchange Rate Versus USD
($m)2
|
||||
Currency
|
|
Primary Relevance
|
|
FY 2016
|
|
YTD 20171
|
|
change %
|
|
Total Revenue
|
|
Core Operating Profit
|
EUR
|
|
Product Sales
|
|
0.90
|
|
0.94
|
|
-4%
|
|
+179
|
|
+123
|
JPY
|
|
Product Sales
|
|
108.84
|
|
115.14
|
|
-5%
|
|
+104
|
|
+71
|
CNY
|
|
Product Sales
|
|
6.65
|
|
6.87
|
|
-3%
|
|
+131
|
|
+74
|
SEK
|
|
Costs
|
|
8.56
|
|
8.97
|
|
-5%
|
|
+7
|
|
-98
|
GBP
|
|
Costs
|
|
0.74
|
|
0.81
|
|
-9%
|
|
+29
|
|
-131
|
Other3
|
|
|
|
|
|
|
|
|
|
+194
|
|
+124
|
1Based
on average daily spot rates between 1st January and 30th January
2017
2Based
on 2016 actual results at 2016 actual exchange
rates
3Other
important currencies include AUD, BRL, CAD, KRW and
RUB
|
Regulatory
Submission Acceptances
|
8
|
- durvalumab - bladder cancer
(US)
- Tagrisso - lung cancer (AURA3 trial) (US,
EU)
- Faslodex
- breast cancer (1L)
(US, EU)
- roxadustat - anaemia (CN) (rolling
submission)
- benralizumab - severe, uncontrolled asthma (US,
EU)
|
Other Key Developments
|
2
|
-
Priority Review Designation: durvalumab (US)
- Priority Review Designation: Tagrisso (US)
|
New Molecular Entities(NMEs) In Phase III TrialsOr Under Regulatory
Review*#
|
12
|
Oncology
-
durvalumab* - multiple cancers
-
durva + treme - multiple cancers
-
acalabrutinib - blood cancers
-
moxetumomab pasudotox - leukaemia
-
selumetinib - thyroid cancer
Cardiovascular & Metabolic Diseases
- ZS-9* - hyperkalaemia
-
roxadustat* - anaemia
Respiratory
-
benralizumab* - severe, uncontrolled asthma
-
tralokinumab - severe, uncontrolled asthma
-
PT010 - COPD
Other
-
anifrolumab - lupus
-
AZD3293 - Alzheimer's disease
|
Projects in clinical pipeline#
|
120
|
|
Name
|
Phase
|
Line of Treatment
|
Population
|
Design
|
Timelines
|
Status
|
Combination therapy
|
||||||
DANUBE
|
III
|
1st Line
|
Cisplatin chemo-
therapy- eligible/
ineligible bladder cancer
|
durvalumab, durva + treme vs SoC chemotherapy
|
FPD1
Q4 2015
First data anticipated 2018
|
Ongoing
|
LUNG CANCER
|
||||||
Name
|
Phase
|
Line of Treatment
|
Population
|
Design
|
Timelines
|
Status
|
Monotherapy
|
||||||
ADJUVANT2
|
III
|
N/A
|
Stage Ib-IIIa NSCLC
|
durvalumab vs placebo
|
FPD Q1 2015
First data anticipated 2020
|
Ongoing
|
PACIFIC
|
III
|
N/A
|
Stage III unresectable NSCLC
|
durvalumab vs placebo
|
FPD Q2 2014
LPCD3
Q2 2016
First data anticipated H2 2017
|
Recruitment completed
|
PEARL
|
III
|
1st line
|
NSCLC (Asia)
|
durvalumab vs SoC chemotherapy
|
First data anticipated 2020
|
Initiating
|
Combination therapy
|
||||||
MYSTIC
|
III
|
1st line
|
NSCLC
|
durvalumab, durva + treme vs SoC chemotherapy
|
FPD Q3 2015LPCD Q3 2016
First data anticipated mid-2017
|
Recruitment completed
|
NEPTUNE
|
III
|
1st line
|
NSCLC
|
durva + treme vs SoC chemotherapy
|
FPD Q4
2015
First data anticipated 2018
|
Ongoing
|
-
|
III
|
1st line
|
NSCLC
|
durvalumab + chemotherapy +/- tremelimumab
|
-
|
Ongoing in safety lead-in Phase I/II trial
|
ARCTIC
|
III
|
3rd line
|
PD-L1 neg. NSCLC
|
durvalumab, tremelimumab, durva + treme vs SoC
chemotherapy
|
FPD Q2 2015
LPCD Q3 2016
First data anticipated H1 2017
|
Recruitment completed
|
CASPIAN
|
III
|
1st line
|
Small-cell lung cancer
|
durvalumab + SoC, durva + treme + SoC vs SoC
chemotherapy
|
-
|
Initiating
|
Name
|
Phase
|
Line of Treatment
|
Population
|
Design
|
Timelines
|
Status
|
|
Combination therapy
|
|||||||
KESTREL
|
III
|
1st line
|
HNSCC*
|
durvalumab, durva + treme vs SoC
|
FPD Q4 2015
First data anticipated H2 2017
|
Ongoing
|
|
EAGLE
|
III
|
2nd line
|
HNSCC
|
durvalumab, durva + treme vs SoC
|
FPD Q4 2015
First data anticipated 2018
|
Ongoing
|
Medicine
|
Trial
|
Mode of Action
|
Number of Patients
|
Primary Endpoint
|
Timeline
|
Bydureon
|
EXSCEL
|
GLP-1 agonist
|
~14,000
|
Time to first occurrence of CV death, non-fatal MI or non-fatal
stroke
|
Latest 2018
(final analysis)
|
Farxiga
|
DECLARE
|
SGLT2 inhibitor
|
~17,000*
|
Time to first occurrence of CV death, non-fatal MI or non-fatal
stroke
|
Latest 2019
(final analysis)
|
Compound
|
Mechanism
|
Area Under Investigation
|
Date Commenced Phase
|
Estimated Regulatory Acceptance Date / Submission
Status
|
|||
US
|
EU
|
Japan
|
China
|
||||
Oncology
|
|||||||
Faslodex
FALCON
|
oestrogen receptor antagonist
|
1st-line hormone receptor +ve advanced breast cancer
|
|
Accepted
|
Accepted
|
Accepted
|
H2 2017
|
Lynparza OlympiAD
|
PARP inhibitor
|
gBRCA metastatic breast cancer
|
Q2 2014
|
H2 2017
|
H2 2017
|
H2 2017
|
|
LynparzaSOLO-2
|
PARP inhibitor
|
2nd-line or greater BRCAm PSR ovarian cancer, maintenance
monotherapy
|
Q3 2013
|
H1 2017
(Fast Track)
|
H1 2017
|
H2 2017
|
|
LynparzaSOLO-1
|
PARP inhibitor
|
1st-line BRCAm ovarian cancer
|
Q3 2013
|
2018
|
2018
|
2018
|
|
LynparzaSOLO-3
|
PARP inhibitor
|
gBRCA PSR ovarian cancer
|
Q1 2015
|
2018
|
|
|
|
LynparzaPOLO
|
PARP inhibitor
|
pancreatic cancer
|
Q1 2015
|
2018
|
2018
|
|
|
Lynparza
|
PARP inhibitor
|
prostate cancer
|
Q3 2014
|
(Breakthrough
Therapy)
|
|
|
|
Lynparza
OlympiA
|
PARP inhibitor
|
gBRCA adjuvant breast cancer
|
Q2 2014
|
2020
|
2020
|
2020
|
|
Tagrisso
FLAURA
|
EGFR inhibitor
|
1st-line advanced EGFRm NSCLC
|
Q1 2015
|
H2 2017
|
H2 2017
|
H2 2017
|
H2 2017
|
Tagrisso
ADAURA
|
EGFR inhibitor
|
adjuvant EGFRm NSCLC
|
Q4 2015
|
2022
|
2022
|
2022
|
2022
|
Cardiovascular & Metabolic Diseases
|
|||||||
Brilinta1PEGASUS-TIMI
54
|
P2Y12 receptor antagonist
|
outcomes trial in patients with prior myocardial
infarction
|
|
Launched
(Priority Review)
|
Launched
|
Approved
|
Accepted
|
Brilinta1
THEMIS
|
P2Y12 receptor antagonist
|
outcomes trial in patients with type-2 diabetes and CAD, but
without a previous history of myocardial infarction or
stroke
|
Q1 2014
|
2018
|
2018
|
2018
|
2019
|
Brilinta1
HESTIA
|
P2Y12 receptor antagonist
|
prevention of vaso-occlusive crises in paediatric patients with
sickle cell disease
|
Q1 2014
|
2020
|
2020
|
|
|
Onglyza
SAVOR-TIMI 53
|
DPP-4 inhibitor
|
type-2 diabetes outcomes trial
|
|
Launched
|
Launched
|
|
Accepted
|
Kombiglyze XR/Komboglyze2
|
DPP-4 inhibitor/ metformin FDC
|
type-2 diabetes
|
|
Launched
|
Launched
|
|
Accepted
|
Farxiga3DECLARE-TIMI
58
|
SGLT2 inhibitor
|
type-2 diabetes outcomes trial
|
Q2 2013
|
2020
|
2020
|
|
|
Farxiga3
|
SGLT2 inhibitor
|
type-1 diabetes
|
Q4 2014
|
2018
|
2018
|
2018
|
|
Xigduo XR/
Xigduo4
|
SGLT2 inhibitor/ metformin FDC
|
type-2 diabetes
|
|
Launched
|
Launched
|
|
|
Qtern (saxagliptin/
dapagliflozin FDC)
|
DPP-4 inhibitor/ SGLT2 inhibitor FDC
|
type-2 diabetes
|
|
Accepted
|
Approved
|
|
|
Bydureon weeklysuspension
|
GLP-1 receptor agonist
|
type-2 diabetes
|
Q1 2013
|
H1 2017
|
H2 2017
|
|
|
Bydureon EXSCEL
|
GLP-1 receptor agonist
|
type-2 diabetes outcomes trial
|
Q2 2010
|
2018
|
2018
|
|
2018
|
Epanova
STRENGTH
|
omega-3 carboxylic acids
|
outcomes trial in statin-treated patients at high CV risk, with
persistent hypertriglyceridemia plus low
HDL-cholesterol
|
Q4 2014
|
2020
|
2020
|
2020
|
2020
|
Respiratory
|
|||||||
Symbicort
SYGMA
|
ICS/LABA
|
as-needed use in mild asthma
|
Q4 2014
|
|
2018
|
|
2019
|
Symbicort
|
ICS/LABA
|
breath actuated Inhaler asthma/COPD
|
|
2018
|
|
|
|
Duaklir Genuair#
|
LAMA/LABA
|
COPD
|
|
2018
|
Launched
|
|
2019
|
Other
|
|||||||
Nexium
|
proton pump inhibitor
|
stress ulcer prophylaxis
|
|
|
|
|
Submitted
|
Nexium
|
proton pump inhibitor
|
paediatrics
|
|
Launched
|
Launched
|
Accepted
|
|
linaclotide#
|
GC-C receptor peptide agonist
|
irritable bowel syndrome with constipation(IBS-C)
|
|
|
|
|
Accepted
|
Compound
|
Mechanism
|
Area Under Investigation
|
Phase
|
Date Commenced Phase
|
|
|
|||||
Oncology
|
|
||||
durvalumab#
|
PD-L1 mAb
|
solid tumours
|
II
|
Q3
2014
|
|
durvalumab#
+ tremelimumab
|
PD-L1
mAb + CTLA-4 mAb
|
Hepatocellular carcinoma (liver cancer)
|
II
|
Q4
2016
|
|
durvalumab#
+ tremelimumab
|
PD-L1
mAb + CTLA-4 mAb
|
gastric
cancer
|
II
|
Q2
2015
|
|
durvalumab#
+ AZD5069
|
PD-L1 mAb + CXCR2
|
HNSCC
|
II
|
Q3
2015
|
|
durvalumab#
+ AZD9150#
|
PD-L1 mAb + STAT3 inhibitor
|
|
|||
durvalumab#
+ dabrafenib +
trametinib
|
PD-L1 mAb+ BRAF inhibitor + MEK inhibitor
|
melanoma
|
II
|
Q1
2014
|
|
durvalumab#
+ AZD1775#
|
PD-L1 mAb + Wee1 inhibitor
|
solid tumours
|
I
|
Q4 2015
|
|
durvalumab#
+ MEDI0680
|
PD-L1 mAb + PD-1 mAb
|
solid tumours
|
I
|
Q3
2016
|
|
durvalumab# or durvalumab# + (tremelimumab or
AZD9150#)
|
PD-L1 mAb or PD-L1 mAb + (CTLA-4 mAb or STAT3
inhibitor)
|
diffuse large B-cell lymphoma
|
I
|
Q3
2016
|
|
durvalumab# +
Iressa
|
PD-L1 mAb+ EGFR inhibitor
|
NSCLC
|
I
|
Q2
2014
|
|
durvalumab#
+ MEDI0562#
|
PD-L1 mAb + humanised OX40 agonist
|
solid tumours
|
I
|
Q2 2016
|
|
durvalumab#
+ MEDI9447
|
PD-L1 mAb + CD73 mAb
|
solid tumours
|
I
|
Q1
2016
|
|
durvalumab#
+ monalizumab
|
PD-L1 mAb + NKG2a mAb
|
solid tumours
|
I
|
Q1
2016
|
|
durvalumab#
+ selumetinib
|
PD-L1 mAb + MEK inhibitor
|
solid tumours
|
I
|
Q4
2015
|
|
durvalumab#
+ tremelimumab
|
PD-L1 mAb + CTLA-4 mAb
|
solid tumours
|
I
|
Q4
2013
|
|
tremelimumab + MEDI0562#
|
CTLA-4 mAb + humanised OX40 agonist
|
solid tumours
|
I
|
Q2 2016
|
|
Lynparza + AZD6738
|
PARP inhibitor + ATR inhibitor
|
gastric cancer
|
II
|
Q3
2016
|
|
Lynparza +
AZD1775#
|
PARP inhibitor + Wee1 inhibitor
|
solid tumours
|
I
|
Q3 2015
|
|
savolitinib#
|
MET inhibitor
|
papillary renal cell carcinoma
|
II
|
Q2
2014
|
|
Tagrisso +
(selumetinib#
or savolitinib#)
TATTON
|
EGFR inhibitor + (MEK inhibitor or MET inhibitor)
|
advanced EGFRm NSCLC
|
II
|
Q2
2016
|
|
Tagrisso BLOOM
|
EGFR
inhibitor
|
CNS metastases in advanced EGFRm NSCLC
|
II
|
Q4
2015
|
|
AZD1775#
+ chemotherapy
|
Wee1 inhibitor + chemotherapy
|
ovarian cancer
|
II
|
Q4 2012
|
|
AZD1775#
|
Wee1 inhibitor
|
solid tumours
|
II
|
Q1 2016
|
|
vistusertib
(AZD2014)
|
mTOR inhibitor
|
solid tumours
|
II
|
Q1
2013
|
|
AZD5363#
|
AKT inhibitor
|
breast cancer
|
II
|
Q1
2014
|
|
AZD4547
|
FGFR inhibitor
|
solid tumours
|
II
|
Q4
2011
|
|
MEDI-573#
|
IGF mAb
|
metastatic breast cancer
|
II
|
Q2
2012
|
|
AZD0156
|
ATM inhibitor
|
solid tumours
|
I
|
Q4
2015
|
|
AZD2811#
|
Aurora B inhibitor
|
solid tumours
|
I
|
Q4
2015
|
|
AZD4635
|
A2aR inhibitor
|
solid tumours
|
I
|
Q2 2016
|
|
AZD6738
|
ATR inhibitor
|
solid tumours
|
I
|
Q4
2013
|
|
AZD8186
|
PI3k inhibitor
|
solid tumours
|
I
|
Q2
2013
|
|
AZD9150#
|
STAT3 inhibitor
|
haematological malignancies
|
I
|
Q1
2012
|
|
AZD9496
|
selective oestrogen receptor downregulator (SERD)
|
ER+ breast cancer
|
I
|
Q4 2014
|
|
MEDI-565#
|
CEA BiTE mAb
|
solid tumours
|
I
|
Q1
2011
|
|
MEDI0562#
|
humanised OX40 agonist
|
solid tumours
|
I
|
Q1 2015
|
|
MEDI0680
|
PD-1 mAb
|
solid tumours
|
I
|
Q4
2013
|
|
MEDI1873
|
GITR agonist fusion protein
|
solid tumours
|
I
|
Q4
2015
|
|
MEDI4276
|
HER2 bispecific ADC mAb
|
solid tumours
|
I
|
Q4
2015
|
|
MEDI9197#
|
TLR 7/8 agonist
|
solid tumours
|
I
|
Q4
2015
|
|
MEDI9447
|
CD73 mAb
|
solid tumours
|
I
|
Q3
2015
|
|
Cardiovascular & Metabolic Diseases
|
|
||||
MEDI0382
|
GLP-1/
glucagon dual agonist
|
diabetes / obesity
|
II
|
Q3
2016
|
|
MEDI4166
|
PCSK9/GLP-1 mAb + peptide fusion
|
diabetes / cardiovascular
|
II
|
Q1
2016
|
|
MEDI6012
|
LCAT
|
ACS
|
II
|
Q4
2015
|
|
AZD4076
|
anti-miR103/107 oligonucleotide
|
non-alcoholic fatty liver disease/non-alcoholic steatohepatitis
(NASH)
|
II
|
Q4
2016
|
|
AZD4831
|
Myeloperoxidase
|
Heart failure with a preserved ejection fraction
|
I
|
Q3
2016
|
|
AZD5718
|
FLAP
|
CAD
|
I
|
Q1
2016
|
|
AZD8601#
|
VEGF-A
|
cardiovascular
|
I
|
Q1
2017
|
|
MEDI8111
|
Rh-factor II
|
trauma / bleeding
|
I
|
Q1
2014
|
|
Respiratory
|
|
||||
tezepelumab#
|
TSLP mAb
|
asthma / atopic dermatitis
|
II
|
Q2
2014
|
|
abediterol#
|
LABA
|
asthma/COPD
|
II
|
Q4
2007
|
|
AZD7594
|
inhaled SGRM
|
asthma/COPD
|
II
|
Q3
2015
|
|
AZD9412#
|
inhaled interferon beta
|
asthma/COPD
|
II
|
Q3
2015
|
|
PT010
|
LABA/LAMA/ICS
|
asthma
|
II
|
Q2
2014
|
|
AZD1419#
|
TLR9 agonist
|
asthma
|
II
|
Q4
2016
|
|
AZD8871#
|
MABA
|
COPD
|
II
|
Q1
2017
|
|
AZD0284
|
Inhaled RORg
|
psoriasis
|
I
|
Q4
2016
|
|
AZD5634
|
inhaled ENaC
|
cystic fibrosis
|
I
|
Q1
2016
|
|
AZD7594+abediterol#
|
Inhaled SGRM+LABA
|
asthma/COPD
|
I
|
Q4
2016
|
|
AZD7986#
|
DPP1
|
COPD
|
I
|
Q4
2014
|
|
AZD9567
|
oral SGRM
|
rheumatoid arthritis
|
I
|
Q4
2015
|
|
Other
|
|
||||
anifrolumab#
|
IFN-alphaR mAb
|
lupus nephritis
|
II
|
Q4
2015
|
|
anifrolumab#
|
IFN-alphaR mAb
|
systemic lupus erythematosus (subcutaneous)
|
I
|
Q4
2015
|
|
inebilizumab#
|
CD19 mAb
|
neuromyelitis optica
|
II
|
Q1
2015
(Orphan
drug)
|
|
mavrilimumab#
|
GM-CSFR mAb
|
rheumatoid arthritis
|
II
|
Q1
2010
|
|
verinurad1
|
selective
uric acid reabsorption inhibitor (URAT-1)
|
chronic treatment of hyperuricemia in patients with
gout
|
II
|
Q3
2013
|
|
MEDI5872#
|
B7RP1 mAb
|
primary
Sjögren's
syndrome
|
II
|
Q3
2016
|
|
AZD3241
|
myeloperoxidase inhibitor
|
multiple system atrophy
|
II
|
Q2
2015
(Orphan
drug)
|
|
MEDI3902
|
Psl/PcrV bispecific mAb
|
prevention of nosocomial pseudomonas pneumonia
|
II
|
Q2
2016
(Fast Track, US)
|
|
MEDI4893
|
mAb binding to S. aureus toxin
|
hospital-acquired pneumonia / serious S. aureus infection
|
II
|
Q4
2014
(Fast Track, US)
|
|
MEDI8852
|
influenza A mAb
|
influenza A treatment
|
II
|
Q4
2015
(Fast
Track, US)
|
|
MEDI8897#
|
RSV mAb-YTE
|
passive RSV prophylaxis
|
II
|
Q1
2015
(Fast Track, US)
|
|
MEDI0700#
|
BAFF/B7RP1 bispecific mAb
|
systemic lupus erythematosus
|
I
|
Q1
2016
|
|
MEDI1814#2
|
amyloid beta mAb
|
Alzheimer's disease
|
I
|
Q2
2014
|
|
MEDI4920
|
anti-CD40L-Tn3 fusion protein
|
primary Sjögren's syndrome
|
I
|
Q2
2014
|
|
MEDI7352
|
NGF/TNF bispecific mAb
|
osteoarthritis pain
|
I
|
Q1
2016
|
|
MEDI7734
|
ILT7 mAb
|
myositis
|
I
|
Q3
2016
|
|
MEDI9314
|
IL-4R mAb
|
atopic dermatitis
|
I
|
Q1
2016
|
|
Compound
|
Mechanism
|
Area Under Investigation
|
Date Commenced Phase
|
Estimated Regulatory Acceptance Date / Submission
Status
|
|||
US
|
EU
|
Japan
|
China
|
||||
Oncology
|
|||||||
Faslodex
FALCON
|
oestrogen receptor antagonist
|
1st-line hormone receptor +ve advanced breast cancer
|
|
Accepted
|
Accepted
|
Accepted
|
H2 2017
|
Lynparza OlympiAD
|
PARP inhibitor
|
gBRCA metastatic breast cancer
|
Q2 2014
|
H2 2017
|
H2 2017
|
H2 2017
|
|
LynparzaSOLO-2
|
PARP inhibitor
|
2nd-line or greater BRCAm PSR ovarian cancer, maintenance
monotherapy
|
Q3 2013
|
H1 2017
(Fast Track)
|
H1 2017
|
H2 2017
|
|
LynparzaSOLO-1
|
PARP inhibitor
|
1st-line BRCAm ovarian cancer
|
Q3 2013
|
2018
|
2018
|
2018
|
|
LynparzaSOLO-3
|
PARP inhibitor
|
gBRCA PSR ovarian cancer
|
Q1 2015
|
2018
|
|
|
|
LynparzaPOLO
|
PARP inhibitor
|
pancreatic cancer
|
Q1 2015
|
2018
|
2018
|
|
|
Lynparza
|
PARP inhibitor
|
prostate cancer
|
Q3 2014
|
(Breakthrough
Therapy)
|
|
|
|
Lynparza
OlympiA
|
PARP inhibitor
|
gBRCA adjuvant breast cancer
|
Q2 2014
|
2020
|
2020
|
2020
|
|
Tagrisso
FLAURA
|
EGFR inhibitor
|
1st-line advanced EGFRm NSCLC
|
Q1 2015
|
H2 2017
|
H2 2017
|
H2 2017
|
H2 2017
|
Tagrisso
ADAURA
|
EGFR inhibitor
|
adjuvant EGFRm NSCLC
|
Q4 2015
|
2022
|
2022
|
2022
|
2022
|
Cardiovascular & Metabolic Diseases
|
|||||||
Brilinta1PEGASUS-TIMI
54
|
P2Y12 receptor antagonist
|
outcomes trial in patients with prior myocardial
infarction
|
|
Launched
(Priority Review)
|
Launched
|
Approved
|
Accepted
|
Brilinta1
THEMIS
|
P2Y12 receptor antagonist
|
outcomes trial in patients with type-2 diabetes and CAD, but
without a previous history of myocardial infarction or
stroke
|
Q1 2014
|
2018
|
2018
|
2018
|
2019
|
Brilinta1
HESTIA
|
P2Y12 receptor antagonist
|
prevention of vaso-occlusive crises in paediatric patients with
sickle cell disease
|
Q1 2014
|
2020
|
2020
|
|
|
Onglyza
SAVOR-TIMI 53
|
DPP-4 inhibitor
|
type-2 diabetes outcomes trial
|
|
Launched
|
Launched
|
|
Accepted
|
Kombiglyze XR/Komboglyze2
|
DPP-4 inhibitor/ metformin FDC
|
type-2 diabetes
|
|
Launched
|
Launched
|
|
Accepted
|
Farxiga3DECLARE-TIMI
58
|
SGLT2 inhibitor
|
type-2 diabetes outcomes trial
|
Q2 2013
|
2020
|
2020
|
|
|
Farxiga3
|
SGLT2 inhibitor
|
type-1 diabetes
|
Q4 2014
|
2018
|
2018
|
2018
|
|
Xigduo XR/
Xigduo4
|
SGLT2 inhibitor/ metformin FDC
|
type-2 diabetes
|
|
Launched
|
Launched
|
|
|
Qtern (saxagliptin/
dapagliflozin FDC)
|
DPP-4 inhibitor/ SGLT2 inhibitor FDC
|
type-2 diabetes
|
|
Accepted
|
Approved
|
|
|
Bydureon weeklysuspension
|
GLP-1 receptor agonist
|
type-2 diabetes
|
Q1 2013
|
H1 2017
|
H2 2017
|
|
|
Bydureon EXSCEL
|
GLP-1 receptor agonist
|
type-2 diabetes outcomes trial
|
Q2 2010
|
2018
|
2018
|
|
2018
|
Epanova
STRENGTH
|
omega-3 carboxylic acids
|
outcomes trial in statin-treated patients at high CV risk, with
persistent hypertriglyceridemia plus low
HDL-cholesterol
|
Q4 2014
|
2020
|
2020
|
2020
|
2020
|
Respiratory
|
|||||||
Symbicort
SYGMA
|
ICS/LABA
|
as-needed use in mild asthma
|
Q4 2014
|
|
2018
|
|
2019
|
Symbicort
|
ICS/LABA
|
breath actuated Inhaler asthma/COPD
|
|
2018
|
|
|
|
Duaklir Genuair#
|
LAMA/LABA
|
COPD
|
|
2018
|
Launched
|
|
2019
|
Other
|
|||||||
Nexium
|
proton pump inhibitor
|
stress ulcer prophylaxis
|
|
|
|
|
Submitted
|
Nexium
|
proton pump inhibitor
|
paediatrics
|
|
Launched
|
Launched
|
Accepted
|
|
linaclotide#
|
GC-C receptor peptide agonist
|
irritable bowel syndrome with constipation(IBS-C)
|
|
|
|
|
Accepted
|
NME / Line Extension
|
Compound
|
Reason for Discontinuation
|
Area Under Investigation
|
NME
|
durvalumab#
+ tremelimumab
ALPS¶
|
Safety/Efficacy
|
metastatic
pancreatic ductal carcinoma
|
NME
|
MEDI7510
|
Safety/Efficacy
|
Prevention of respiratory syncytial virus disease in older
patients
|
Compound
|
Mechanism
|
Area Under Investigation
|
Completed/
Divested
|
Estimated Regulatory Submission Acceptance†
|
|||
US
|
EU
|
Japan
|
China
|
||||
MEDI2070#1
|
IL-23 mAb
|
Crohn's disease
|
Divested
|
|
|
|
|
Zinforo#2
|
extended
spectrum cephalosporin with affinity to penicillin-binding
proteins
|
pneumonia/skin
infections
|
Divested
|
|
Launched
|
|
Submitted
|
Zavicefta#2
(CAZ
AVI)
|
cephalosporin/
beta lactamase inhibitor
|
hospital-acquired
pneumonia/ ventilator-associated pneumonia
|
Divested
|
|
Approved
|
|
|
Zavicefta#2
(CAZ
AVI)
|
cephalosporin/
beta lactamase inhibitor
|
serious
infections, complicated intra-abdominal infection, complicated
urinary tract infection
|
Divested
|
|
Approved
|
|
|
ATM
AVI#2
|
monobactam/ beta lactamase inhibitor
|
targeted serious bacterial infections
|
Divested
|
|
|
|
|
CXL#2
|
beta lactamase inhibitor / cephalosporin
|
methicillin-resistant S. aureus
|
Divested
|
|
|
|
|
AZD8108
|
NMDA antagonist
|
suicidal ideation
|
Divested
|
|
|
|
|
durvalumab#HAWK¶3
|
PD-L1
mAb
|
2nd-line
HNSCC (PD-L1 positive)
|
Completed
|
|
|
|
|
durvalumab#
+ tremelimumabCONDOR¶3
|
PD-L1
mAb + CTLA-4 mAb
|
2nd-line
HNSCC (PD-L1 negative)
|
Completed
|
|
|
|
|
For the
year ended 31
December
|
|
2016
$m
|
|
2015
$m
|
Product
sales
|
|
21,319
|
|
23,641
|
Externalisation
revenue
|
|
1,683
|
|
1,067
|
Total revenue
|
|
23,002
|
|
24,708
|
Cost of
sales
|
|
(4,126)
|
|
(4,646)
|
Gross profit
|
|
18,876
|
|
20,062
|
Distribution
costs
|
|
(326)
|
|
(339)
|
Research
and development expense
|
|
(5,890)
|
|
(5,997)
|
Selling,
general and administrative costs
|
|
(9,413)
|
|
(11,112)
|
Other
operating income and expense
|
|
1,655
|
|
1,500
|
Operating profit
|
|
4,902
|
|
4,114
|
Finance
income
|
|
67
|
|
46
|
Finance
expense
|
|
(1,384)
|
|
(1,075)
|
Share
of after tax losses in associates and joint ventures
|
|
(33)
|
|
(16)
|
Profit before tax
|
|
3,552
|
|
3,069
|
Taxation
|
|
(146)
|
|
(243)
|
Profit for the period
|
|
3,406
|
|
2,826
|
|
|
|
|
|
Other comprehensive income
|
|
|
|
|
Items that will not be reclassified to profit or loss
|
|
|
|
|
Remeasurement
of the defined benefit pension liability
|
|
(575)
|
|
652
|
Tax on
items that will not be reclassified to profit or loss
|
|
136
|
|
(199)
|
|
|
(439)
|
|
453
|
Items that may be reclassified subsequently to profit or
loss
|
|
|
|
|
Foreign
exchange arising on consolidation
|
|
(1,050)
|
|
(528)
|
Foreign
exchange arising on designating borrowings in net investment
hedges
|
|
(591)
|
|
(333)
|
Fair
value movements on cash flow hedges
|
|
(115)
|
|
-
|
Fair
value movements on cash flow hedges transferred to profit or
loss
|
|
195
|
|
-
|
Fair
value movements on derivatives designated in net investment
hedges
|
|
(4)
|
|
14
|
Amortisation
of loss on cash flow hedge
|
|
1
|
|
1
|
Net
available for sale gains/(losses) taken to equity
|
|
139
|
|
(32)
|
Tax on
items that may be reclassified subsequently to profit or
loss
|
|
86
|
|
87
|
|
|
(1,339)
|
|
(791)
|
Other comprehensive income for the period, net of tax
|
|
(1,778)
|
|
(338)
|
Total comprehensive income for the period
|
|
1,628
|
|
2,488
|
|
|
|
|
|
Profit attributable to:
|
|
|
|
|
Owners
of the Parent
|
|
3,499
|
|
2,825
|
Non-controlling
interests
|
|
(93)
|
|
1
|
|
|
3,406
|
|
2,826
|
|
|
|
|
|
Total comprehensive income attributable to:
|
|
|
|
|
Owners
of the Parent
|
|
1,722
|
|
2,488
|
Non-controlling
interests
|
|
(94)
|
|
-
|
|
|
1,628
|
|
2,488
|
|
|
|
|
|
Basic
earnings per $0.25 Ordinary Share
|
|
$2.77
|
|
$2.23
|
Diluted
earnings per $0.25 Ordinary Share
|
|
$2.76
|
|
$2.23
|
Weighted
average number of Ordinary Shares in issue (millions)
|
|
1,265
|
|
1,264
|
Diluted
weighted average number of Ordinary Shares in issue
(millions)
|
|
1,266
|
|
1,265
|
For the
quarter ended 31
December
|
|
2016
$m
|
|
2015
$m
|
Product
sales
|
|
5,260
|
|
6,207
|
Externalisation
revenue
|
|
325
|
|
192
|
Total revenue
|
|
5,585
|
|
6,399
|
Cost of
sales
|
|
(1,160)
|
|
(1,269)
|
Gross profit
|
|
4,425
|
|
5,130
|
Distribution
costs
|
|
(83)
|
|
(99)
|
Research
and development expense
|
|
(1,543)
|
|
(1,746)
|
Selling,
general and administrative costs
|
|
(1,386)
|
|
(2,668)
|
Other
operating income and expense
|
|
1,120
|
|
471
|
Operating profit
|
|
2,533
|
|
1,088
|
Finance
income
|
|
23
|
|
13
|
Finance
expense
|
|
(362)
|
|
(292)
|
Share
of after tax losses in associates and joint ventures
|
|
(11)
|
|
(7)
|
Profit before tax
|
|
2,183
|
|
802
|
Taxation
|
|
(366)
|
|
6
|
Profit for the period
|
|
1,817
|
|
808
|
|
|
|
|
|
Other comprehensive income
|
|
|
|
|
Items that will not be reclassified to profit or loss
|
|
|
|
|
Remeasurement
of the defined benefit pension liability
|
|
552
|
|
618
|
Tax on
items that will not be reclassified to profit or loss
|
|
(120)
|
|
(187)
|
|
|
432
|
|
431
|
Items that may be reclassified subsequently to profit or
loss
|
|
|
|
|
Foreign
exchange arising on consolidation
|
|
(360)
|
|
(169)
|
Foreign
exchange arising on designating borrowings in net investment
hedges
|
|
(397)
|
|
(11)
|
Fair
value movements on cash flow hedges
|
|
(89)
|
|
-
|
Fair
value movements on cash flow hedges transferred to profit or
loss
|
|
154
|
|
-
|
Fair
value movements on derivatives designated in net investment
hedges
|
|
92
|
|
(10)
|
Net
available for sale gains taken to equity
|
|
13
|
|
31
|
Tax on
items that may be reclassified subsequently to profit or
loss
|
|
23
|
|
3
|
|
|
(564)
|
|
(156)
|
Other comprehensive income for the period, net of tax
|
|
(132)
|
|
275
|
Total comprehensive income for the period
|
|
1,685
|
|
1,083
|
|
|
|
|
|
Profit attributable to:
|
|
|
|
|
Owners
of the Parent
|
|
1,842
|
|
808
|
Non-controlling
interests
|
|
(25)
|
|
-
|
|
|
1,817
|
|
808
|
|
|
|
|
|
Total comprehensive income attributable to:
|
|
|
|
|
Owners
of the Parent
|
|
1,710
|
|
1,083
|
Non-controlling
interests
|
|
(25)
|
|
-
|
|
|
1,685
|
|
1,083
|
|
|
|
|
|
Basic
earnings per $0.25 Ordinary Share
|
|
$1.46
|
|
$0.63
|
Diluted
earnings per $0.25 Ordinary Share
|
|
$1.45
|
|
$0.63
|
Weighted
average number of Ordinary Shares in issue (millions)
|
|
1,265
|
|
1,264
|
Diluted
weighted average number of Ordinary Shares in issue
(millions)
|
|
1,266
|
|
1,265
|
|
|
At
31 Dec 2016
$m
|
|
Restated*
At
31 Dec 2015
$m
|
ASSETS
Non-current
assets
|
|
|
|
|
Property, plant and
equipment
|
|
6,848
|
|
6,413
|
Goodwill
|
|
11,658
|
|
11,800
|
Intangible
assets
|
|
27,586
|
|
22,646
|
Derivative
financial instruments
|
|
343
|
|
446
|
Investments in
associates and joint ventures
|
|
99
|
|
85
|
Other
investments
|
|
727
|
|
458
|
Other
receivables
|
|
901
|
|
907
|
Deferred tax
assets
|
|
1,102
|
|
1,294
|
|
|
49,264
|
|
44,049
|
Current
assets
|
|
|
|
|
Inventories
|
|
2,334
|
|
2,143
|
Trade
and other receivables
|
|
4,573
|
|
6,622
|
Other
investments
|
|
884
|
|
613
|
Derivative
financial instruments
|
|
27
|
|
2
|
Income
tax receivable
|
|
426
|
|
387
|
Cash
and cash equivalents
|
|
5,018
|
|
6,240
|
|
|
13,262
|
|
16,007
|
Total
assets
|
|
62,526
|
|
60,056
|
LIABILITIES
Current
liabilities
|
|
|
|
|
Interest-bearing
loans and borrowings
|
|
(2,307)
|
|
(916)
|
Trade
and other payables
|
|
(10,486)
|
|
(11,663)
|
Derivative
financial instruments
|
|
(18)
|
|
(9)
|
Provisions
|
|
(1,065)
|
|
(798)
|
Income
tax payable
|
|
(1,380)
|
|
(1,483)
|
|
|
(15,256)
|
|
(14,869)
|
Non-current
liabilities
|
|
|
|
|
Interest-bearing
loans and borrowings
|
|
(14,501)
|
|
(14,137)
|
Derivative
financial instruments
|
|
(117)
|
|
(1)
|
Deferred tax
liabilities
|
|
(3,956)
|
|
(2,665)
|
Retirement benefit
obligations
|
|
(2,186)
|
|
(1,974)
|
Provisions
|
|
(353)
|
|
(444)
|
Other
payables
|
|
(9,488)
|
|
(7,457)
|
|
|
(30,601)
|
|
(26,678)
|
Total
liabilities
|
|
(45,857)
|
|
(41,547)
|
Net
assets
|
|
16,669
|
|
18,509
|
EQUITY
|
|
|
|
|
Capital
and reserves attributable to equity holders of the
Company
|
|
|
|
|
Share
capital
|
|
316
|
|
316
|
Share
premium account
|
|
4,351
|
|
4,304
|
Other
reserves
|
|
2,047
|
|
2,036
|
Retained
earnings
|
|
8,140
|
|
11,834
|
|
|
14,854
|
|
18,490
|
Non-controlling
interests
|
|
1,815
|
|
19
|
Total
equity
|
|
16,669
|
|
18,509
|
|
|
|
|
|
For the
year ended 31 December
|
|
2016
$m
|
|
2015
$m
|
Cash
flows from operating activities
|
|
|
|
|
Profit
before tax
|
|
3,552
|
|
3,069
|
Finance
income and expense
|
|
1,317
|
|
1,029
|
Share
of after tax losses in associates and joint ventures
|
|
33
|
|
16
|
Depreciation,
amortisation and impairment
|
|
2,357
|
|
2,852
|
Decrease/(increase)
in working capital and short-term provisions
|
|
926
|
|
(49)
|
Gain on
disposal of intangible assets
|
|
(1,301)
|
|
(961)
|
Fair
value movements on contingent consideration arising from business
combinations
|
|
(1,158)
|
|
(432)
|
Non-cash and other
movements
|
|
(492)
|
|
(350)
|
Cash
generated from operations
|
|
5,234
|
|
5,174
|
Interest
paid
|
|
(677)
|
|
(496)
|
Tax
paid
|
|
(412)
|
|
(1,354)
|
Net
cash inflow from operating activities
|
|
4,145
|
|
3,324
|
Cash
flows from investing activities
|
|
|
|
|
Movement in
short-term investments and fixed deposits
|
|
(166)
|
|
283
|
Purchase of
property, plant and equipment
|
|
(1,446)
|
|
(1,328)
|
Disposal of
property, plant and equipment
|
|
82
|
|
47
|
Purchase of
intangible assets
|
|
(868)
|
|
(1,460)
|
Disposal of
intangible assets
|
|
1,427
|
|
1,130
|
Purchase of
non-current asset investments
|
|
(230)
|
|
(57)
|
Disposal of
non-current asset investments
|
|
3
|
|
93
|
Payments to joint
ventures
|
|
(41)
|
|
(45)
|
Upfront
payments on business combinations
|
|
(2,564)
|
|
(2,446)
|
Payment
of contingent consideration from business combinations
|
|
(293)
|
|
(579)
|
Interest
received
|
|
140
|
|
123
|
Payments made by
subsidiaries to non-controlling interests
|
|
(13)
|
|
-
|
Net
cash outflow from investing activities
|
|
(3,969)
|
|
(4,239)
|
Net
cash inflow/(outflow) before financing activities
|
|
176
|
|
(915)
|
Cash
flows from financing activities
|
|
|
|
|
Proceeds from issue
of share capital
|
|
47
|
|
43
|
New
long-term loans
|
|
2,491
|
|
5,928
|
Repayment of
loans
|
|
-
|
|
(884)
|
Dividends
paid
|
|
(3,561)
|
|
(3,486)
|
Hedge
contracts relating to dividend payments
|
|
18
|
|
(51)
|
Repayment of
obligations under finance leases
|
|
(16)
|
|
(42)
|
Movement in
short-term borrowings
|
|
(303)
|
|
(630)
|
Net
cash (outflow)/inflow from financing activities
|
|
(1,324)
|
|
878
|
Net
decrease in cash and cash equivalents in the period
|
|
(1,148)
|
|
(37)
|
Cash
and cash equivalents at the beginning of the period
|
|
6,051
|
|
6,164
|
Exchange rate
effects
|
|
21
|
|
(76)
|
Cash
and cash equivalents at the end of the period
|
|
4,924
|
|
6,051
|
Cash
and cash equivalents consists of:
|
|
|
|
|
Cash
and cash equivalents
|
|
5,018
|
|
6,240
|
Overdrafts
|
|
(94)
|
|
(189)
|
|
|
4,924
|
|
6,051
|
|
|
|
|
|
|
|
Sharecapital$m
|
|
Sharepremiumaccount$m
|
|
Otherreserves*$m
|
|
Retainedearnings$m
|
|
Total $m
|
|
Non-controllinginterests$m
|
|
Totalequity$m
|
|
|
|
|||||||||||||
At
1 Jan 2015
|
|
316
|
|
4,261
|
|
2,021
|
|
13,029
|
|
19,627
|
|
19
|
|
19,646
|
|
|
|
|||||||||||||
Profit
for the period
|
|
-
|
|
-
|
|
-
|
|
2,825
|
|
2,825
|
|
1
|
|
2,826
|
|
|
|
|||||||||||||
Other
comprehensive income
|
|
-
|
|
-
|
|
-
|
|
(337)
|
|
(337)
|
|
(1)
|
|
(338)
|
|
|
|
|||||||||||||
Transfer to other
reserves
|
|
-
|
|
-
|
|
15
|
|
(15)
|
|
-
|
|
-
|
|
-
|
|
|
|
|||||||||||||
Transactions
with owners:
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|||||||||||||
Dividends
|
|
-
|
|
-
|
|
-
|
|
(3,537)
|
|
(3,537)
|
|
-
|
|
(3,537)
|
|
|
|
|||||||||||||
Issue
of Ordinary Shares
|
|
-
|
|
43
|
|
-
|
|
-
|
|
43
|
|
-
|
|
43
|
|
|
|
|||||||||||||
Share-based
payments
|
|
-
|
|
-
|
|
-
|
|
(131)
|
|
(131)
|
|
-
|
|
(131)
|
|
|
|
|||||||||||||
Net
movement
|
|
-
|
|
43
|
|
15
|
|
(1,195)
|
|
(1,137)
|
|
-
|
|
(1,137)
|
|
|
|
|||||||||||||
At
31 Dec 2015
|
|
316
|
|
4,304
|
|
2,036
|
|
11,834
|
|
18,490
|
|
19
|
|
18,509
|
|
|
|
|||||||||||||
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|||||||||||||
|
|
Sharecapital$m
|
|
Sharepremiumaccount$m
|
|
Otherreserves*$m
|
|
Retainedearnings$m
|
|
Total $m
|
|
Non-controllinginterests$m
|
|
Totalequity$m
|
|
|
|
|||||||||||||
At
1 Jan 2016
|
|
316
|
|
4,304
|
|
2,036
|
|
11,834
|
|
18,490
|
|
19
|
|
18,509
|
|
|
|
|||||||||||||
Profit
for the period
|
|
-
|
|
-
|
|
-
|
|
3,499
|
|
3,499
|
|
(93)
|
|
3,406
|
|
|
|
|||||||||||||
Other
comprehensive income
|
|
-
|
|
-
|
|
-
|
|
(1,777)
|
|
(1,777)
|
|
(1)
|
|
(1,778)
|
|
|
|
|||||||||||||
Transfer to other
reserves
|
|
-
|
|
-
|
|
11
|
|
(11)
|
|
-
|
|
-
|
|
-
|
|
|
|
|||||||||||||
Transactions
with owners:
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|||||||||||||
Dividends
|
|
-
|
|
-
|
|
-
|
|
(3,540)
|
|
(3,540)
|
|
-
|
|
(3,540)
|
|
|
|
|||||||||||||
Dividend paid by
subsidiary to non-controlling interest
|
|
-
|
|
-
|
|
-
|
|
-
|
|
-
|
|
(13)
|
|
(13)
|
|
|
|
|||||||||||||
Acerta
put option
|
|
-
|
|
-
|
|
-
|
|
(1,825)
|
|
(1,825)
|
|
-
|
|
(1,825)
|
|
|
|
|||||||||||||
Changes
in non-controlling interest
|
|
-
|
|
-
|
|
-
|
|
-
|
|
-
|
|
1,903
|
|
1,903
|
|
|
|
|||||||||||||
Issue
of Ordinary Shares
|
|
-
|
|
47
|
|
-
|
|
-
|
|
47
|
|
-
|
|
47
|
|
|
|
|||||||||||||
Share-based
payments
|
|
-
|
|
-
|
|
-
|
|
(40)
|
|
(40)
|
|
-
|
|
(40)
|
|
|
|
|||||||||||||
Net
movement
|
|
-
|
|
47
|
|
11
|
|
(3,694)
|
|
(3,636)
|
|
1,796
|
|
(1,840)
|
|
|
|
|||||||||||||
At
31 Dec 2016
|
|
316
|
|
4,351
|
|
2,047
|
|
8,140
|
|
14,854
|
|
1,815
|
|
16,669
|
|
|
|
|||||||||||||
* Other
reserves include the capital redemption reserve and the merger
reserve.
|
|
|
||||||||||||||||||||||||||||
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
FY
2016$m
|
|
FY
2015$m
|
|
Q4
2016$m
|
|
Q4
2015$m
|
Cost of
sales
|
|
130
|
|
158
|
|
43
|
|
34
|
Research and
development expense
|
|
178
|
|
258
|
|
32
|
|
78
|
Selling, general
and administrative costs
|
|
823
|
|
618
|
|
319
|
|
260
|
Other
operating income and expense
|
|
(24)
|
|
-
|
|
-
|
|
-
|
Total
|
|
1,107
|
|
1,034
|
|
394
|
|
372
|
|
|
At 1 Jan
2016
$m
|
|
Cash
Flow
$m
|
|
Acquisitions
$m
|
|
Non-cash
&
Other
$m
|
|
Exchange
Movements
$m
|
|
At
31 Dec
2016
$m
|
Loans
due after one year
|
|
(14,109)
|
|
(2,491)
|
|
-
|
|
1,793
|
|
312
|
|
(14,495)
|
Finance
leases due after one year
|
|
(28)
|
|
-
|
|
-
|
|
22
|
|
-
|
|
(6)
|
Total
long-term debt
|
|
(14,137)
|
|
(2,491)
|
|
-
|
|
1,815
|
|
312
|
|
(14,501)
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Current
instalments of loans
|
|
-
|
|
-
|
|
-
|
|
(1,769)
|
|
-
|
|
(1,769)
|
Current
instalments of finance leases
|
|
(67)
|
|
16
|
|
-
|
|
(37)
|
|
1
|
|
(87)
|
Total
current debt
|
|
(67)
|
|
16
|
|
-
|
|
(1,806)
|
|
1
|
|
(1,856)
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Other
Investments
|
|
613
|
|
164
|
|
140
|
|
54
|
|
(73)
|
|
898
|
Net
derivative financial instruments
|
|
438
|
|
(2)
|
|
-
|
|
(201)
|
|
-
|
|
235
|
Cash
and cash equivalents
|
|
6,240
|
|
(1,231)
|
|
-
|
|
-
|
|
9
|
|
5,018
|
Overdrafts
|
|
(189)
|
|
83
|
|
-
|
|
-
|
|
12
|
|
(94)
|
Short-term
borrowings
|
|
(660)
|
|
303
|
|
-
|
|
1
|
|
(1)
|
|
(357)
|
|
|
6,442
|
|
(683)
|
|
140
|
|
(146)
|
|
(53)
|
|
5,700
|
Net
debt
|
|
(7,762)
|
|
(3,158)
|
|
140
|
|
(137)
|
|
260
|
|
(10,657)
|
|
Fair value
$m
|
Intangible
assets
|
7,307
|
Other
assets including cash and cash equivalents
|
253
|
Deferred
tax liabilities
|
(1,777)
|
Other
liabilities
|
(90)
|
Total net assets acquired
|
5,693
|
Non-controlling
interests
|
(1,903)
|
Goodwill
|
19
|
Fair value of total consideration
|
3,809
|
Less:
fair value of deferred consideration
|
(1,332)
|
Total upfront consideration
|
2,477
|
Less:
cash and cash equivalents acquired
|
(94)
|
Net cash outflow
|
2,383
|
|
Fair
value
$m
|
Non-current
assets
|
|
Intangible
assets
|
3,162
|
Property, plant and
equipment
|
21
|
|
3,183
|
Current
assets
|
169
|
Current
liabilities
|
(50)
|
Non-current
liabilities
|
|
Deferred tax
liabilities
|
(977)
|
Other
liabilities
|
(13)
|
|
(990)
|
Total
net assets acquired
|
2,312
|
Goodwill
|
388
|
Total
upfront consideration
|
2,700
|
Less:
cash and cash equivalents acquired
|
(73)
|
Less:
deferred upfront consideration
|
(181)
|
Net
cash outflow
|
2,446
|
|
|
Diabetes
Alliance
2016
|
|
Other
2016
|
|
Total
2016
|
|
Total
2015
|
|
|
$m
|
|
$m
|
|
$m
|
|
$m
|
At
1 January
|
|
5,092
|
|
1,319
|
|
6,411
|
|
6,899
|
Settlements
|
|
(242)
|
|
(51)
|
|
(293)
|
|
(579)
|
Revaluations
|
|
(999)
|
|
(159)
|
|
(1,158)
|
|
(432)
|
Discount
unwind
|
|
389
|
|
108
|
|
497
|
|
524
|
Foreign
exchange
|
|
-
|
|
-
|
|
-
|
|
(1)
|
At
31 December
|
|
4,240
|
|
1,217
|
|
5,457
|
|
6,411
|
|
|
World
|
|
US
|
|
Europe
|
|
Established ROW
|
|
Emerging Markets
|
||||||||||
|
|
FY 2016
$m
|
|
CER
%
|
|
FY 2016
$m
|
|
CER
%
|
|
FY 2016
$m
|
|
CER
%
|
|
FY 2016
$m
|
|
CER
%
|
|
FY 2016
$m
|
|
CER
%
|
Oncology:
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Iressa
|
|
513
|
|
(5)
|
|
23
|
|
n/m
|
|
120
|
|
(5)
|
|
137
|
|
(8)
|
|
233
|
|
(10)
|
Tagrisso
|
|
423
|
|
n/m
|
|
254
|
|
n/m
|
|
76
|
|
n/m
|
|
83
|
|
100
|
|
10
|
|
100
|
Lynparza
|
|
218
|
|
n/m
|
|
127
|
|
81
|
|
81
|
|
n/m
|
|
3
|
|
n/m
|
|
7
|
|
n/m
|
Legacy:
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Faslodex
|
|
830
|
|
19
|
|
438
|
|
23
|
|
228
|
|
11
|
|
68
|
|
15
|
|
96
|
|
25
|
Zoladex
|
|
816
|
|
-
|
|
35
|
|
25
|
|
156
|
|
(4)
|
|
270
|
|
(7)
|
|
355
|
|
6
|
Casodex
|
|
247
|
|
(9)
|
|
2
|
|
100
|
|
27
|
|
(7)
|
|
111
|
|
(23)
|
|
107
|
|
8
|
Arimidex
|
|
232
|
|
(6)
|
|
14
|
|
(26)
|
|
37
|
|
(24)
|
|
71
|
|
(18)
|
|
110
|
|
15
|
Others
|
|
104
|
|
(26)
|
|
-
|
|
n/m
|
|
8
|
|
(65)
|
|
71
|
|
7
|
|
25
|
|
(13)
|
Total Oncology
|
|
3,383
|
|
20
|
|
893
|
|
74
|
|
733
|
|
18
|
|
814
|
|
2
|
|
943
|
|
6
|
Cardiovascular & Metabolic
Diseases:
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Brilinta
|
|
839
|
|
39
|
|
348
|
|
45
|
|
258
|
|
15
|
|
44
|
|
22
|
|
189
|
|
80
|
Farxiga
|
|
835
|
|
72
|
|
457
|
|
75
|
|
187
|
|
52
|
|
58
|
|
72
|
|
133
|
|
96
|
Onglyza
|
|
720
|
|
(6)
|
|
376
|
|
(10)
|
|
132
|
|
(5)
|
|
70
|
|
11
|
|
142
|
|
(4)
|
Bydureon
|
|
578
|
|
-
|
|
463
|
|
(4)
|
|
100
|
|
23
|
|
11
|
|
25
|
|
4
|
|
(25)
|
Byetta
|
|
254
|
|
(19)
|
|
164
|
|
(22)
|
|
45
|
|
(25)
|
|
21
|
|
(9)
|
|
24
|
|
13
|
Legacy:
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Crestor
|
|
3,401
|
|
(32)
|
|
1,223
|
|
(57)
|
|
866
|
|
(4)
|
|
591
|
|
(5)
|
|
721
|
|
12
|
Seloken/Toprol-XL
|
|
737
|
|
9
|
|
95
|
|
7
|
|
90
|
|
(5)
|
|
16
|
|
25
|
|
536
|
|
12
|
Atacand
|
|
315
|
|
(8)
|
|
36
|
|
6
|
|
97
|
|
(8)
|
|
20
|
|
(20)
|
|
162
|
|
(9)
|
Others
|
|
437
|
|
(26)
|
|
40
|
|
(27)
|
|
119
|
|
(17)
|
|
50
|
|
(21)
|
|
228
|
|
(30)
|
Total Cardiovascular & Metabolic
Diseases
|
|
8,116
|
|
(13)
|
|
3,202
|
|
(31)
|
|
1,894
|
|
1
|
|
881
|
|
(1)
|
|
2,139
|
|
8
|
Respiratory:
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Symbicort
|
|
2,989
|
|
(10)
|
|
1,242
|
|
(18)
|
|
909
|
|
(12)
|
|
436
|
|
5
|
|
402
|
|
10
|
Pulmicort
|
|
1,061
|
|
8
|
|
174
|
|
(13)
|
|
99
|
|
(14)
|
|
90
|
|
(3)
|
|
698
|
|
21
|
Tudorza/Eklira
|
|
170
|
|
(9)
|
|
77
|
|
(25)
|
|
83
|
|
9
|
|
9
|
|
-
|
|
1
|
|
n/m
|
Daliresp/Daxas
|
|
154
|
|
48
|
|
134
|
|
29
|
|
15
|
|
100
|
|
1
|
|
n/m
|
|
4
|
|
n/m
|
Duaklir
|
|
63
|
|
n/m
|
|
-
|
|
-
|
|
60
|
|
n/m
|
|
2
|
|
n/m
|
|
1
|
|
n/m
|
Others
|
|
316
|
|
27
|
|
11
|
|
(39)
|
|
118
|
|
38
|
|
50
|
|
108
|
|
137
|
|
13
|
Total Respiratory
|
|
4,753
|
|
(3)
|
|
1,638
|
|
(16)
|
|
1,284
|
|
(4)
|
|
588
|
|
8
|
|
1,243
|
|
17
|
Other:
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Nexium
|
|
2,032
|
|
(18)
|
|
554
|
|
(39)
|
|
251
|
|
(11)
|
|
537
|
|
(10)
|
|
690
|
|
(3)
|
Seroquel XR
|
|
735
|
|
(27)
|
|
515
|
|
(28)
|
|
134
|
|
(32)
|
|
17
|
|
(32)
|
|
69
|
|
(7)
|
Synagis
|
|
677
|
|
2
|
|
325
|
|
14
|
|
352
|
|
(7)
|
|
-
|
|
-
|
|
-
|
|
-
|
Losec/Prilosec
|
|
276
|
|
(17)
|
|
10
|
|
(44)
|
|
83
|
|
(13)
|
|
55
|
|
(31)
|
|
128
|
|
(9)
|
FluMist/Fluenz
|
|
104
|
|
(59)
|
|
33
|
|
(84)
|
|
64
|
|
3
|
|
6
|
|
(14)
|
|
1
|
|
n/m
|
Movantik/Moventig
|
|
91
|
|
n/m
|
|
90
|
|
n/m
|
|
-
|
|
-
|
|
-
|
|
-
|
|
1
|
|
-
|
Others
|
|
1,152
|
|
(20)
|
|
105
|
|
(54)
|
|
269
|
|
(21)
|
|
198
|
|
(27)
|
|
580
|
|
(4)
|
Total Other
|
|
5,067
|
|
(19)
|
|
1,632
|
|
(31)
|
|
1,153
|
|
(15)
|
|
813
|
|
(17)
|
|
1,469
|
|
(4)
|
Total Product Sales
|
|
21,319
|
|
(8)
|
|
7,365
|
|
(22)
|
|
5,064
|
|
(3)
|
|
3,096
|
|
(4)
|
|
5,794
|
|
6
|
|
|
World
|
|
US
|
|
Europe
|
|
Established ROW
|
|
Emerging Markets
|
|||||||||||||||
|
|
Q4 2016
$m
|
|
CER
%
|
|
Q4 2016
$m
|
|
CER %
|
|
Q4 2016
$m
|
|
CER
%
|
|
Q4 2016
$m
|
|
CER
%
|
|
Q4 2016
$m
|
|
CER
%
|
|
||||
Oncology:
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
||||
Iressa
|
|
118
|
|
(11)
|
|
7
|
|
75
|
|
29
|
|
(6)
|
|
36
|
|
(6)
|
|
46
|
|
(22)
|
|
||||
Tagrisso
|
|
147
|
|
n/m
|
|
74
|
|
n/m
|
|
27
|
|
n/m
|
|
40
|
|
100
|
|
6
|
|
n/m
|
|
||||
Lynparza
|
|
62
|
|
72
|
|
31
|
|
29
|
|
25
|
|
127
|
|
3
|
|
n/m
|
|
3
|
|
n/m
|
|
||||
Legacy:
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
||||
Faslodex
|
|
222
|
|
19
|
|
117
|
|
23
|
|
59
|
|
11
|
|
20
|
|
20
|
|
26
|
|
23
|
|
||||
Zoladex
|
|
235
|
|
13
|
|
8
|
|
33
|
|
39
|
|
2
|
|
71
|
|
(9)
|
|
117
|
|
36
|
|
||||
Casodex
|
|
60
|
|
(8)
|
|
-
|
|
-
|
|
8
|
|
14
|
|
27
|
|
(27)
|
|
25
|
|
13
|
|
||||
Arimidex
|
|
57
|
|
(7)
|
|
2
|
|
(50)
|
|
10
|
|
(17)
|
|
18
|
|
(24)
|
|
27
|
|
22
|
|
||||
Others
|
|
29
|
|
-
|
|
-
|
|
-
|
|
4
|
|
33
|
|
20
|
|
6
|
|
5
|
|
(29)
|
|
||||
Total Oncology
|
|
930
|
|
26
|
|
239
|
|
61
|
|
201
|
|
26
|
|
235
|
|
11
|
|
255
|
|
16
|
|
||||
Cardiovascular & Metabolic
Diseases:
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
||||
Brilinta
|
|
236
|
|
37
|
|
105
|
|
50
|
|
66
|
|
13
|
|
12
|
|
10
|
|
53
|
|
62
|
|
||||
Farxiga
|
|
239
|
|
57
|
|
130
|
|
69
|
|
51
|
|
37
|
|
17
|
|
50
|
|
41
|
|
56
|
|
||||
Onglyza
|
|
149
|
|
(21)
|
|
72
|
|
(27)
|
|
30
|
|
(6)
|
|
15
|
|
(17)
|
|
32
|
|
(23)
|
|
||||
Bydureon
|
|
142
|
|
(8)
|
|
114
|
|
(7)
|
|
25
|
|
(7)
|
|
3
|
|
50
|
|
-
|
|
n/m
|
|
||||
Byetta
|
|
55
|
|
(22)
|
|
37
|
|
(14)
|
|
8
|
|
(43)
|
|
5
|
|
(29)
|
|
5
|
|
(25)
|
|
||||
Legacy:
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
||||
Crestor
|
|
631
|
|
(53)
|
|
95
|
|
(88)
|
|
209
|
|
(6)
|
|
146
|
|
(16)
|
|
181
|
|
14
|
|
||||
Seloken/Toprol-XL
|
|
178
|
|
14
|
|
14
|
|
(26)
|
|
23
|
|
(4)
|
|
6
|
|
67
|
|
135
|
|
23
|
|
||||
Atacand
|
|
81
|
|
(5)
|
|
8
|
|
14
|
|
23
|
|
(12)
|
|
5
|
|
25
|
|
45
|
|
(6)
|
|
||||
Others
|
|
100
|
|
(31)
|
|
13
|
|
(7)
|
|
30
|
|
(21)
|
|
12
|
|
(29)
|
|
45
|
|
(41)
|
|
||||
Total Cardiovascular & Metabolic Diseases
|
|
1,811
|
|
(26)
|
|
588
|
|
(52)
|
|
465
|
|
(3)
|
|
221
|
|
(11)
|
|
537
|
|
6
|
|
||||
Respiratory:
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
||||
Symbicort
|
|
740
|
|
(13)
|
|
284
|
|
(31)
|
|
230
|
|
(3)
|
|
126
|
|
15
|
|
100
|
|
5
|
|
||||
Pulmicort
|
|
288
|
|
8
|
|
36
|
|
(31)
|
|
26
|
|
(10)
|
|
29
|
|
-
|
|
197
|
|
25
|
|
||||
Tudorza/Eklira
|
|
36
|
|
(23)
|
|
16
|
|
(36)
|
|
18
|
|
(5)
|
|
2
|
|
-
|
|
-
|
|
n/m
|
|
||||
Daliresp/Daxas
|
|
41
|
|
28
|
|
33
|
|
3
|
|
5
|
|
100
|
|
-
|
|
-
|
|
3
|
|
n/m
|
|
||||
Duaklir
|
|
19
|
|
58
|
|
-
|
|
-
|
|
18
|
|
46
|
|
1
|
|
n/m
|
|
-
|
|
-
|
|
||||
Others
|
|
86
|
|
37
|
|
4
|
|
(33)
|
|
35
|
|
85
|
|
17
|
|
143
|
|
30
|
|
(3)
|
|
||||
Total Respiratory
|
|
1,210
|
|
(5)
|
|
373
|
|
(29)
|
|
332
|
|
5
|
|
175
|
|
19
|
|
330
|
|
16
|
|
||||
Other:
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
||||
Nexium
|
|
491
|
|
(15)
|
|
135
|
|
(23)
|
|
61
|
|
(19)
|
|
148
|
|
(5)
|
|
147
|
|
(12)
|
|
||||
Seroquel XR
|
|
118
|
|
(51)
|
|
71
|
|
(60)
|
|
28
|
|
(32)
|
|
3
|
|
(40)
|
|
16
|
|
(16)
|
|
||||
Synagis
|
|
302
|
|
10
|
|
154
|
|
20
|
|
148
|
|
1
|
|
-
|
|
-
|
|
-
|
|
-
|
|
||||
Losec/Prilosec
|
|
59
|
|
(23)
|
|
3
|
|
100
|
|
20
|
|
(19)
|
|
13
|
|
(33)
|
|
23
|
|
(30)
|
|
||||
FluMist/Fluenz
|
|
67
|
|
(60)
|
|
20
|
|
(83)
|
|
43
|
|
(21)
|
|
4
|
|
(43)
|
|
-
|
|
-
|
|
||||
Movantik/Moventig
|
|
26
|
|
73
|
|
26
|
|
73
|
|
-
|
|
-
|
|
-
|
|
-
|
|
-
|
|
-
|
|
||||
Others
|
|
246
|
|
(34)
|
|
9
|
|
(84)
|
|
34
|
|
(57)
|
|
25
|
|
(69)
|
|
178
|
|
8
|
|
||||
Total Other
|
|
1,309
|
|
(25)
|
|
418
|
|
(38)
|
|
334
|
|
(21)
|
|
193
|
|
(28)
|
|
364
|
|
(5)
|
|
||||
Total Product Sales
|
|
5,260
|
|
(15)
|
|
1,618
|
|
(37)
|
|
1,332
|
|
(3)
|
|
824
|
|
(6)
|
|
1,486
|
|
7
|
|
Announcement of
first quarter 2017 results
|
27
April 2017
|
Annual
General Meeting
|
27
April 2017
|
Announcement of
half year and second quarter 2017 results
|
27 July
2017
|
Announcement of
nine months and third quarter 2017 results
|
9
November 2017
|
|
Addresses
for Correspondence
|
|||
Registered Office
1
Francis Crick Avenue
Cambridge
Biomedical Campus, Cambridge
CB2
0AA
UK
|
Registrar and
Transfer Office
Equiniti
Limited
Aspect
House
Spencer
Road
Lancing
West
Sussex
BN99
6DA
UK
|
Swedish Central Securities Depository
Euroclear
Sweden AB
PO Box
191
SE-101
23 Stockholm
Sweden
|
US Depositary
Citibank Shareholder Services
PO Box
43077
Providence
RI
02940-3077
USA
|
Tel:
+44 (0)20 3749 5000
|
Tel
(freephone in UK):
0800
389 1580
Tel
(outside UK): +44 (0)121 415 7033
|
Tel:
+46 (0)8 402 9000
|
Tel:
(toll free in the US)
+1
(888) 697 8018
Tel:
(outside the US)
+1
(781) 575 4555
citibank@shareholders-online.com
|
|
|
|
|
Cautionary
Statements Regarding Forward-Looking Statements
|
|
AstraZeneca
PLC
|
|
By: /s/
Adrian Kemp
|
|
Name:
Adrian Kemp
|
|
Title:
Company Secretary
|